Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 1
1990 2
1991 3
1992 2
1993 2
1994 6
1995 8
1996 7
1997 14
1998 14
1999 8
2000 5
2001 15
2002 16
2003 12
2004 11
2005 8
2006 4
2007 3
2008 4
2009 3
2010 3
2011 3
2012 3
2013 3
2014 2
2015 1
2016 6
2017 6
2018 8
2019 9
2020 3
2021 5
2022 4
2023 2
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Alternatives to antibiotics-a pipeline portfolio review.
Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH. Czaplewski L, et al. Among authors: rex jh. Lancet Infect Dis. 2016 Feb;16(2):239-51. doi: 10.1016/S1473-3099(15)00466-1. Epub 2016 Jan 13. Lancet Infect Dis. 2016. PMID: 26795692 Free article. Review.
Deeply invasive candidiasis.
Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ. Ostrosky-Zeichner L, et al. Among authors: rex jh. Infect Dis Clin North Am. 2002 Dec;16(4):821-35. doi: 10.1016/s0891-5520(02)00034-x. Infect Dis Clin North Am. 2002. PMID: 12512183 Review.
Analysis of the clinical antibacterial and antituberculosis pipeline.
Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S. Theuretzbacher U, et al. Among authors: rex jh. Lancet Infect Dis. 2019 Feb;19(2):e40-e50. doi: 10.1016/S1473-3099(18)30513-9. Epub 2018 Oct 15. Lancet Infect Dis. 2019. PMID: 30337260
Developmental roadmap for antimicrobial susceptibility testing systems.
van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, Becker K, Hays JP, Woodford N, Mitsakakis K, Moran-Gilad J, Vila J, Peter H, Rex JH, Dunne WM Jr; JPIAMR AMR-RDT Working Group on Antimicrobial Resistance and Rapid Diagnostic Testing. van Belkum A, et al. Among authors: rex jh. Nat Rev Microbiol. 2019 Jan;17(1):51-62. doi: 10.1038/s41579-018-0098-9. Nat Rev Microbiol. 2019. PMID: 30333569 Free PMC article. Review.
Combination antifungal therapy.
Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Johnson MD, et al. Among authors: rex jh. Antimicrob Agents Chemother. 2004 Mar;48(3):693-715. doi: 10.1128/AAC.48.3.693-715.2004. Antimicrob Agents Chemother. 2004. PMID: 14982754 Free PMC article. Review. No abstract available.
Antifungal susceptibility testing.
Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Rex JH, et al. Clin Microbiol Rev. 1993 Oct;6(4):367-81. doi: 10.1128/CMR.6.4.367. Clin Microbiol Rev. 1993. PMID: 8269392 Free PMC article. Review.
Antibiotic development - economic, regulatory and societal challenges.
Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N. Årdal C, et al. Among authors: rex jh. Nat Rev Microbiol. 2020 May;18(5):267-274. doi: 10.1038/s41579-019-0293-3. Epub 2019 Nov 19. Nat Rev Microbiol. 2020. PMID: 31745330 Review. No abstract available.
Critical analysis of antibacterial agents in clinical development.
Theuretzbacher U, Bush K, Harbarth S, Paul M, Rex JH, Tacconelli E, Thwaites GE. Theuretzbacher U, et al. Among authors: rex jh. Nat Rev Microbiol. 2020 May;18(5):286-298. doi: 10.1038/s41579-020-0340-0. Epub 2020 Mar 9. Nat Rev Microbiol. 2020. PMID: 32152509 Review.
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.
Maertens JA, Thompson GR 3rd, Spec A, Donovan FM, Hammond SP, Bruns AHW, Rahav G, Shoham S, Johnson R, Rijnders B, Schaenman J, Hoenigl M, Morrissey CO, Mehta SR, Heath CH, Koehler P, Paterson DL, Slavin MA, Fortún J, Nguyen MH, Patterson TF, Uspenskaya O, Van de Veerdonk FL, Verweij PE, Aoun M, Georgala A, Alexander BD, Chayakulkeeree M, Mehra V, Miceli MH, Sikka MK, Solé A, Walsh TJ, Aguado JM, Holland SM, Moussa M, Rautemaa-Richardson R, Bazaz R, Schwartz S, Walsh SR, Plate M, Yehudai-Ofir D, Brüggemann RJ, Cornely OA, Ostrosky-Zeichner L, Vazquez JA, White PL, Cornelissen K, Ross GG, Fitton L, Dane A, Zinzi D, Rex JH, Chen SC. Maertens JA, et al. Among authors: rex jh. Lancet Infect Dis. 2025 Nov;25(11):1177-1188. doi: 10.1016/S1473-3099(25)00224-5. Epub 2025 Jun 18. Lancet Infect Dis. 2025. PMID: 40541222 Clinical Trial.
202 results